The purpose of this study was to compare the effects of mephedrone and 3,4-methylenedioxy-methamphetamine (MDMA), as reported by young recreational polydrug users.
Methods:
152 MDMA users and 81 mephedrone users were recruited through snowballing on social network sites. They completed a standard online questionnaire for either mephedrone or MDMA. The questions covered the average amount taken per session, the longest duration of usage in the last 12-months, subjective effects while on-drug, and recovery effects in the days afterwards.
Results:
Mephedrone users reported a significantly longer maximum session of use than MDMA users. Mephedrone users also reported a significantly greater average amount used per session. The majority of on-drug subjective ratings did not differ between drugs, with similar increases in entactogenic effects. Although mephedrone users did report significantly more frequent issues with sleeping, anger and anxiety. In relation to recovery, mephedrone users reported more frequent craving, nasal irritation, paranoia, and relationship difficulties. Mephedrone users also rated general recovery effects as more severe over the seven-day period following use, taking more days to feel normal.
Conclusions:
The acute effects of MDMA and mephedrone were broadly similar. However, the recovery period for mephedrone was more enduring, possibly due to the longer duration of acute session usage.
AllenRPMcCannUDRicaurteGA (1993) Persistent effects of (+/-) 3, 4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on human sleep. Sleep16: 560–564.
2.
Angoa-PérezMKaneMJBriggsDI. (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J Neurochem125: 102–110.
3.
BarrattMJFerrisJAWinstockAR (2014) Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction109: 774–783.
4.
BaylenCARosenbergH (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction101: 933–947.
5.
BoysAMarsdenJStrangJ (2001) Understanding reasons for drug use amongst young people: A functional perspective. Health Educ Res16: 457–469.
6.
BrièreFNFalluJSJanoszM. (2012). Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J Epidemiol Community Health66: 990–994.
7.
BruntTMPoortmanANiesinkRJ. (2011) Instability of the ecstasy market and a new kid on the block: Mephedrone. J Psychopharmacol25: 1543–1547.
8.
Carhart-HarrisRLKingLANuttDJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend118: 19–22.
9.
Centers for Disease Control and Prevention (CDC) (2011) Emergency department visits after use of a drug sold as’ bath salts’. Morb Mortal Wkly Rep60: 624.
10.
ChildressARMozleyPDMcElginW. (1999). Limbic activation during cue-induced cocaine craving. Am J Psych156: 11–18.
11.
CorazzaOAssiSSimonatoP. (2013) Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project. Hum Psychopharm Clin28: 317–323.
12.
CurranHVTravillRA (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA,‘ecstasy’): Week-end ‘high’ followed by mid-week low. Addiction92: 821–831.
13.
CurranHVReesHHoareT. (2004) Empathy and aggression: Two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology173: 425–433.
14.
DavisonDParrottAC (1997) Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects. Hum Psychopharm Clin12: 221–226.
15.
DeehanASavilleE (2003) Calculating The Risk: Recreational Drug Use among Clubbers in the South East of England. Home Office Online Report 43/03. London: Home Office.
16.
Di ChiaraGBassareoVFenuS. (2004) Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology47: 227–241.
17.
European Monitoring Centre for Drugs and Drug Addiction (2010) Risk Assessment Report of a New Psychoactive Substance: 4-Methylmethcathinone (Mephedrone). Lisbon: European Monitoring Centre for Drugs and Drug Addiction. Available at: http://www.drugsandalcohol.ie/13862/ (accessed 20 March 2016).
18.
FarréMPérez-MañáCMateusJ. (2015) A comparison of the clinical abuse liability of MDMA and mephedrone. Clin Ther37: e130.
19.
FreemanTPMorganCJVaughn-JonesJ. (2012) Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’. Addiction107: 792–800.
20.
GerraGZaimovicAGiucastroG. (1998) Serotonergic function after 3, 4-methylene-dioxymethamphetamine (‘Ecstasy’) in humans. Int Clin Psychopharmacol13: 1–9.
21.
GreenARNuttDJ (2014) Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). J Psychopharmacol28: 711.
22.
GreenARKingMVShortallSE. (2014) The preclinical pharmacology of mephedrone; not just MDMA by another name. Br J Pharmacol171: 2251–2268.
23.
GreenARMechanAOElliottJM. (2003) The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev55: 463–508.
24.
HadlockGCWebbKMMcFaddenLM. (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharm Exp Ther339: 530–536.
25.
HarrisDSBaggottMMendelsonJH. (2002) Subjective and hormonal effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl)162: 396–405.
26.
HerzigDABrooksRMohC (2013) Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing. Hum Psychopharm Clin28: 168–182.
27.
JamesDARDAdamsRDSpearsR. (2011) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service.Emerg Med J28: 686–689.
28.
Kapitány-FövényMKertészMWinstockA. (2013) Substitutional potential of mephedrone: An analysis of the subjective effects. Hum Psychopharm Clin28: 308–316.
29.
KehrJIchinoseFYoshitakeS. (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol164: 1949–1958.
30.
KellyJP (2011) Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test Anal3: 439–453.
31.
KishSJLerchJFurukawaY. (2010). Decreased cerebral cortical serotonin transporter binding in ecstasy users: A positron emission tomography/[11C] DASB and structural brain imaging study. Brain133: 1779–1797.
32.
McCannUDRicaurteGA (2007) Effects of (±) 3, 4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. The Scientific World J7: 231–238.
33.
McCannUDMertlMEligulashviliV. (1999) Cognitive performance in (±) 3, 4-methylenedioxymethamphetamine (MDMA,’ecstasy’) users: A controlled study. Psychopharmacology143: 417–425.
McElrathKO’NeillC (2011) Experiences with mephedrone pre-and post-legislative controls: Perceptions of safety and sources of supply. Int J Drug Policy22: 120–127.
36.
MasMFarréMde la TorreR. (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharm Exp Ther290: 136–145.
37.
ParrottAC (2015) Why all stimulant drugs are damaging to recreational users: An empirical overview and psychobiological explanation. Hum Psychopharm Clin30: 213–224.
38.
ParrottACLaskyJ (1998) Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacology139: 261–268.
39.
ParrottACLockJConnerAC. (2008) Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes. Neuropsychobiology57: 165–180.
40.
ParrottACMilaniRMParmarR. (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology159: 77–82.
41.
ParrottACSandsHRJonesL. (2014) Increased cortisol levels in hair of recent Ecstasy/MDMA users. Eur Neuropsychopharmacol24: 369–374.
42.
ParrottACSiskETurnerJJ D (2000) Psychobiological problems in heavy ‘ecstasy’(MDMA) polydrug users. Drug Alcohol Depend60: 105–110.
43.
RandallSJohansonCETancerM. (2009) Effects of acute 3, 4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: A preliminary study. Sleep32: 1513.
44.
ReidLWElifsonKWSterkCE (2007) Hug drug or thug drug? Ecstasy use and aggressive behavior. Violence Vict22: 104–119.
45.
RicaurteGAMcCannUDSzaboZ. (2000) Toxicodynamics and long-term toxicity of the recreational drug, 3, 4- methylenedioxymethamphetamine (MDMA,‘Ecstasy’). Toxicol Lett112: 143–146.
ShortallSEMacerolaAESwabyRT. (2013). Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol23: 1085–1095.
48.
ShulginAT (1986) The background and chemistry of MDMA. J. Psychoactive Drugs18: 291–304.
49.
SmithKMLariveLLRomanelliF (2002) Club drugs: Methylenedioxy-methamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm59: 1067–1076.
50.
SmithZMooreKMeashamF (2009) MDMA powder, pills and crystal: The persistence of ecstasy and the poverty of policy. Drug Alcohol Depend9: 13–19.
51.
SolowijNHallWLeeN (1992) Recreational MDMA use in Sydney: A profile of ‘ecstasy’ users and their experiences with the drug. Brit. J. Addiction87: 1161–1172.
52.
ToppLBreenCKayeS. (2004) Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for ‘party drugs’. Drug Alcohol Depend73: 189–197.
53.
ToppLHandoJDillonP. (1999) Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend55: 105–115.
54.
UosukainenHTackeUWinstockAR (2015) Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy26: 78–83.
55.
Van HoutMCBrennanR (2011) Plant food for thought: A qualitative study of mephedrone use in Ireland. Drugs: Educ Prev Polic18: 371–381.
56.
Van HoutMCBrennanR (2012) Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland. Drugs: Educ Prev Polic19: 156–162.
57.
VardakouIPistosCSpiliopoulouC (2011) Drugs for youth via Internet and the example of mephedrone. Toxicol Lett201: 191–195.
58.
VolkowNDWangGJTelangF . (2006) Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. J Neurosci26: 6583–6588.
59.
VollenweiderFXGammaALiechtiM. (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naive healthy volunteers. Neuropsychopharmacology19: 241–251.
WinstockAR (1991) Chronic paranoid psychosis after misuse of MDMA. Br Med J302: 1150.
62.
WinstockARRamseyJD (2010) Legal highs and the challenges for policy makers. Addiction105: 1685–1687.
63.
WinstockARGriffithsPStewartD (2001) Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend64: 9–17.
64.
WinstockARMitchesonLRDelucaP. (2011a) Mephedrone, new kid for the chop?Addiction106: 154–161.
65.
WinstockAMitchesonLRamseyJ. (2011b) Mephedrone: Use, subjective effects and health risks. Addiction106: 1991–1996
66.
WoodDMDaviesSGreeneSL. (2010a) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol48: 924–927.
67.
WoodDMDaviesSPuchnarewiczM. (2010b) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol6: 327–330.
68.
WoodDMHunterLMeashamF. (2012) Limited use of novel psychoactive substances in South London nightclubs. Q J Med105: 959–964.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
